ESMO 2020 Lung Cancer Conference Report
In Focus: Lung Cancer
Durvalumab Demonstrates Sustained Overall Survival in Unresectable Stage III NSCLC
Amivantamab-Lazertinib Combo for Resistant EGFR-positive NSCLC
Phase III ADAURA Trial: Life-Changing Results for NSCLC and CNS Metastases Sotorasib Active in Patients with KRAS Mutation Shows Promise in NSCLC
PD-L1 Density a New Predictive Biomarker in NSCLC
No Advantage of Post-Op Radiotherapy in Patients with Stage IIIA N2 NSCLC
Bispecific Targeting PD-1 and CTLA-4: New Kids on the Block(ade)
Lorlatinib Outperforms Crizotinib in ALK-Positive Advanced NSCLC